In addition to radiolabeled somatostatin-targeting peptides, a series of PSMA ligands have been identified and radiolabeled with Cu radioisotopes for clinical diagnosis and radionuclide therapy applications in PCa [50,51,52]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.